UBS AM
ALBO

UBS AM’s Albireo Pharma Inc ALBO Stock Holding History

UBS AM’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,337
Closed -$219K – 2813
2022
Q1 		$219K Buy
+7,337
New +$215K ﹤0.01% 2660
2021
Q4 		– Sell
-7,337
Closed -$229K – 2920
2021
Q3 		$229K Hold
7,337
– – ﹤0.01% 2672
2021
Q2 		$258K Buy
7,337
+1,137
+18% +$37K ﹤0.01% 2671
2021
Q1 		$219K Sell
6,200
-500
-7% -$18.5K ﹤0.01% 2551
2020
Q4 		$251K Buy
+6,700
New +$244K ﹤0.01% 2452

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

UBS AM's ALBO Position: Q2 2022 in Review

UBS AM sold out of Albireo Pharma Inc (ALBO) in Q2 2022, closing a stake of 7,337 shares — an estimated $219K sold.

UBS AM first reported a position in ALBO in Q4 2020 and held it in 5 quarters. The position peaked at $258K in Q2 2021. 103 funds tracked by Wall St. Rank hold ALBO as of Q2 2022.

  • UBS AM reported no remaining Albireo Pharma Inc position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 7,337 Albireo Pharma Inc shares in Q2 2022, an estimated $219K.
  • UBS AM first reported a position in Albireo Pharma Inc in Q4 2020 and held it in 5 quarters.
  • UBS AM's Albireo Pharma Inc position peaked at $258K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.